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Background: Thrombopoietin-receptor agonists eltrombopag (EPAG) and romiplostim (ROMI) 
are treatment options for adults with chronic immune thrombocytopenia (cITP) who have had 
an insufficient response to corticosteroids or immunoglobulins.
Methods: A cost-consequence model was developed to evaluate the costs relative to treatment 
success of EPAG, ROMI, and watch and rescue (W&R) in previously treated patients. The primary 
endpoint assessed was severe bleeding, derived from all identified phase III registered clinical 
trials. Health outcomes were compared via indirect treatment comparison. Costs incorporated in 
the model included drug and administration, routine care, rescue medications, bleeding-related 
adverse events, other adverse events, and mortality costs. A trial (26-week) time horizon was 
used, as certain endpoints used in the model were bound to within-trial results.
Results: In the intent-to-treat (ITT) population, the overall estimated cost per patient for EPAG 
was US$66,560 compared to US$91,039 for ROMI and US$30,099 for W&R. Compared 
to the ITT population, the difference in cost between EPAG and ROMI was slightly greater 
in splenectomized patients (US$65,998 for EPAG compared to US$91,485 for ROMI) and 
slightly less in non-splenectomized patients (US$67,151 for EPAG compared to US$91,455 for 
ROMI), though the overall trend remained the same. When assessing cost per severe bleeding 
event avoided in the ITT population, EPAG dominated (less expensive, more effective) ROMI. 
Sensitivity analyses confirmed these results.
Conclusion: EPAG was preferred over ROMI in the treatment of cITP, largely driven by the 
reduction in severe bleeding events associated with its use.
Keywords: chronic immune thrombocytopenia, eltrombopag, romiplostim, cost consequence, 
cost analysis, USA
Introduction
Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by low 
platelet counts and an increased risk of bleeding. Based on best estimates, the age-
adjusted prevalence of ITP in the US is estimated at about 9.5/100,000 persons,1 with 
an annual incidence of 3.3 per 100,000 adults,2 or ~3,900–9,500 new cases diagnosed 
in the US each year.3 A recent study based on US administrative claims data found a 
median age at diagnosis of 53 years.3
Individuals with chronic immune thrombocytopenia (cITP) can have an increased 
risk of bleeding due to reduced platelet counts. This typically manifests as minor 
bleeding (eg, petechiae or bruising of skin, bleeding from nose or gums,), although 
major bleeding can occur.4 To prevent such bleeding episodes, most therapies aim 
to increase platelet counts. Thrombopoietic-receptor agonists (TPO-RAs), such as 
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eltrombopag (EPAG) and romiplostim (ROMI), accomplish 
this by stimulating platelet production.5 In the US, both are 
indicated for the treatment of cITP in adults who have had 
inadequate response to other therapies, including corticoste-
roids, immunoglobulins, and splenectomy.6
Several studies have assessed the cost per responder of 
ROMI,7–10 although they did not compare these costs to EPAG 
and were not in a US setting. To date, there have been no head-
to-head clinical trials comparing EPAG and ROMI, and few 
indirect treatment comparisons (ITCs) have been developed to 
assess the efficacy and safety of these therapies (eg, Allen et al11).
It is important to understand the cost consequences of 
utilizing different second-line options for the treatment of 
cITP. One study12 has described a cost per response analysis 
comparing EPAG to ROMI and “watch and rescue” (W&R) 
and found TPO-RAs to be efficient in achieving treatment 
success with lower costs per treatment success.
However, additional studies are required to better 
understand current utilization, effectiveness of treatment 
modalities, and the impact of clinical outcomes on cITP. 
Here, we present the results of a cost-consequence model 
that compared EPAG to ROMI and W&R among previously 
treated adult patients in the US.
Materials and methods
Model perspective, patient populations, 
and horizon/discounting
A general US payer’s perspective and a time horizon of 26 
weeks were used. The population consisted of adult patients 
with cITP who had an insufficient response to corticosteroids, 
immunoglobulins, or splenectomy. As splenectomy status is 
a key prognostic factor in ITP,13,14 cost-consequence results 
for splenectomized and non-splenectomized patients were 
also reported separately. The trial data cutoff (26 weeks) was 
used for the time horizon, as certain endpoints used in the 
model are bound to within-trial results. This also allows the 
use of direct evidence from the published literature without 
relying on extrapolation techniques that require additional 
assumptions. Discounting was not applied, as the model 
horizon was <1 year. An overview is presented in Figure 1.
Comparators
After performing a targeted literature review, EPAG and 
ROMI, along with W&R (placebo), were determined to 
be included as comparators. The respective trials’ placebo 
groups constituted W&R, as these patients only received 
rescue therapy as needed. Rituximab and splenectomy, while 
common treatment options for ITP, were not included as 
comparators due to significant noncomparability between 
the trial populations.
Efficacy and dosing data were derived from one clinical 
trial for EPAG (Cheng et al5) and one trial for ROMI (Kuter 
et al18).
We performed an ITC that assessed severe bleeding events 
as the primary endpoint. Severe bleeding (WHO grade 3–5) 
was chosen as the primary endpoint for three main reasons: 
1) complete data on severe bleeding were reported for both 
clinical trials; 2) bleeding, unlike endpoints such as platelet 
Figure 1 Model overview.
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response, has direct, tangible, clinical, and economic conse-
quences; and 3) severe bleeding is associated with the most 
serious clinical ramifications in cITP.
iTC
An ITC was performed between EPAG and ROMI, using 
placebo as the treatment anchor. By design, the two included 
studies (Cheng et al5 for EPAG and Kuter et al19 for ROMI) 
had similar baseline characteristics. The most notable differ-
ences at baseline were in the proportion of splenectomized 
patients (36% in the EPAG trial vs 50% in the ROMI trial), 
the proportion of patients who had received three or more 
prior ITP medications (54% in the EPAG trial vs 63% in 
the ROMI trial), and the proportion of patients receiving 
concomitant medications (48% in the EPAG trial vs 31% in 
the ROMI trial).
The designs of the two trials were deemed acceptably 
comparable, but several differences were noted: the EPAG 
trial did not allow tapering of concomitant ITP medication 
during the first 6 weeks of treatment, while the ROMI trial 
allowed dose reduction or discontinuation of ITP medica-
tions during the first 12 weeks of treatment, which may 
have impacted platelet response. The definitions of platelet 
response differed slightly between the two studies: in Cheng 
et al,5 platelet counts >400,000/µL were not considered a 
response, while they were in Kuter et al.19
Rescue treatment duration assumptions varied between 
the two studies, as Cheng et al5 assumed that rescue treatment 
continued until platelet counts returned to normal levels and 
Kuter et al19 assumed that rescued treatment continued for a 
fixed period of 8 weeks. Overall, the two trials were consid-
ered comparable enough to satisfy the transitivity assumption.
Using ITC, ROMI efficacy data were adjusted to match 
the EPAG trial. Therefore, EPAG and W&R (no drug treat-
ment) efficacy data were taken directly from the trial,20 while 
the ROMI data (from Kuter et al19) were adjusted. Frequentist 
Table 1 Patient flow
Baseline Year 1 Year 2 Year 3 Year 4 Year 5 Source
selected population 321,418,820 323,950,017 326,501,147 329,072,367 331,663,836 334,275,713 Us Census22
18 years or older 247,773,209 249,724,441 251,691,039 253,673,124 255,670,819 257,684,245 Us Census22
iTP prevalence in adults (Us data) 23,538 23,724 23,911 24,099 24,289 24,480 segal et al1
ciTP (persistence or chronicity) 15,771 15,895 16,020 16,146 16,273 16,402 Moulis et al17
lack of response to primary therapy 3,154 3,179 3,204 3,229 3,255 3,280 neunert6
splenectomized patients 558 563 567 572 576 581 Boyle et al23
non-splenectomized patients 2,596 2,616 2,637 2,658 2,679 2,700 Boyle et al23
Mortality associated with iTP 170 172 173 174 176 177 Boyle et al23
Abbreviations: iTP, immune thrombocytopenia; ciTP, chronic immune thrombocytopenia.
ITC was used, and 95% confidence intervals were calculated. 
ROMI results were pooled using random-effects models 
(Mantel–Haenszel method), which generated ORs for ROMI 
vs placebo. Classical frequentist ITC was implemented using 
the Bucher (1997) method and 95% CIs.21
Patient flow
Patient flow in the model was based on epidemiology esti-
mates for the US population, presented in Table 1. Annual 
population growth rate for patient flow was assumed to be 
0.79%.22
Efficacy measures
A summary of the efficacy values and the resulting odds 
ratios for treatment vs EPAG in all patients, as well as spe-
nectomized and non-splenectomized patient groups, from 
the respective clinical trials, is presented in Table S1. As was 
mentioned, these raw values were not used in the model and 
were instead matched through ITC by adjusting the ROMI 
efficacy data to match the placebo (W&R) group in the 
EPAG trial. Therefore, W&R results and EPAG results used 
in the model are identical to those of the EPAG trial, while 
the efficacy results for ROMI are adjusted.
The primary efficacy measure was severe bleeding (WHO 
grades 3–5). The WHO bleeding scale used in the trials (rang-
ing from 1 to 5) is the most commonly applied criteria in 
thrombocytopenia and was considered as a valid measure.24
While platelet response is a commonly used primary 
endpoint in ITP, it was not assessed in this analysis. It should 
be noted that the correlation between platelet response and 
bleeding events has not been well characterized and may not 
be a perfect association.15 While platelet count defines the 
diagnosis and is used to evaluate response to therapy in ITP, 
management decisions are driven by the prevention or treat-
ment of bleeding. Therefore, bleeding is ultimately the most 
important endpoint to both patients and decision  makers15 and 
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was therefore considered to be the most important endpoint 
in our analysis.
Severe bleeding was explored further by calculating the 
cost-effectiveness per severe bleeding event avoided (pre-
sented in the “Results” section).
Costs
Total costs associated with each treatment were based on 
the sum of drug costs, bleeding-related costs, routine care, 
drug administration, rescue medications, adverse events 
(all grades presenting in >20% of patients in at least one of 
the included trials), and mortality costs. The proportion of 
patients requiring these resources in each treatment arm was 
derived from the respective clinical trials,18,25 if available, or 
from other published literature (Table 2). In addition to the 
ITT population, splenectomized and non-splenectomized 
subgroups were assessed.
To account for the fact that the available pack sizes of 
drugs may not allow for the exact dose of drug required, wast-
age was applied for dose calculations based on the received 
doses (ie, doses were rounded up to the nearest pack/vial 
size when necessary). Wastage and dose reductions were 
only included for the primary therapies (EPAG and ROMI). 
Table 2 Resource use sources
Resource Unit cost Source
Comparators
•	 EPag Us$10,253.00 (per pack) analysource26
analysource26•	 ROMi Us$6,492.00 (per pack)
Routine medical costs
•	 laboratory visits Us$27.00 (per visit) saleh et al27
•	 Office visits Us$78.00 (per visit)
•	 Other outpatient visits Us$367.00 (per visit)
•	 Emergency department visits Us$260.00 (per visit)
Rescue treatments
•	 Blood transfusion
•	 iV immunoglobulin
•	 iV methylprednisolone
Us$424.90 (per transfusion)
Us$37.89 (per “pack”)
Us$3.73 (per “pack”)
Utilization
lee et al28
Costs
Blood transfusions: Toner et al29; iVig and iV methylprednisolone: 
Medicare asP Drug Pricing Files30
Bleeding costs (with and without 
hospitalization)
Us$2,196 (without hospitalization)
Us$44,590 (with hospitalization)
lin et al31
Mortality costs Us$55,238 (for iTP) hCUP33
administration costs
•	 subcutaneous injection
•	 iV
•	 Oral
Us$75.19 (per use)
Us$136.41 (per use)
Us$0.00 (per use)
CMs Medicare Fee schedule32
Current Procedural Terminology codes 96413 (chemotherapy 
administration, intravenous infusion technique; up to 1 hour, single 
or initial substance/drug) and 96401 (chemotherapy administration, 
subcutaneous or intramuscular, non-hormonal anti-neoplastic)
adverse events (refer Table s9 for specific  
prevalence and costs)
Prevalence: Cheng et al25, Kuter et al;18 costs: hCUP33
Notes: All costs are reported in USD. No currency conversion was required, as all cost data were derived from US-based sources. US inflation (3.6%) was applied when 
no current (2016) cost data were available.35
Abbreviations: asP, average selling price; EPag, eltrombopag; ROMi, romiplostim; iV, intravenous; iVig, intravenous immunoglobulin; iTP, immune thrombocytopenia; 
hCUP, healthcare Cost and Utilization Project.
A breakdown of the cost calculations are presented in Tables 
S2–S4.
Included costs were summed to obtain the total cost 
associated with each primary therapy. Resources used in the 
analysis and their sources are summarized in Table 2.
Probabilistic sensitivity analyses (Psas)
Uncertainty in the results was assessed with PSAs, where 
probabilistic distributions were directly applied to the base 
case model for the ITT, splenectomized, and non-splenec-
tomized populations. All efficacy and cost parameters were 
explored in the PSA and are presented in the “Results” 
section.
Results
The summed overall costs and efficacy results for each 
primary therapy are shown in Table 3. Specific costs and 
the raw efficacy data from the clinical trials are presented 
in Tables S3–S10. As was mentioned, efficacy data from 
the ITC were used in the model, where the ROMI efficacy 
data was adjusted to match the placebo (W&R) group to the 
EPAG trial. Therefore, W&R results and EPAG results used 
in the model are identical to those of the EPAG trial, while the 
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efficacy results for ROMI are adjusted (as described earlier). 
After ITC, severe bleeding rates in ROMI-treated patients 
decreased to 3.7% from the 7.1% reported in the trial, as the 
placebo group in the Kuter et al19 study experienced a higher 
severe bleeding rate than that in the EPAG trial.5
In the ITT populations, EPAG, ROMI, and W&R had total 
estimated costs of US$66,560, US$91,039, and US$30,099, 
respectively. In this population, EPAG was estimated to cost 
US$24,480 (26.9%) less than ROMI. Compared with W&R, 
EPAG costs US$36,460 (121.1%) more, while ROMI costs 
US$60,940 (202.5%) more.
In the splenectomized population, EPAG was estimated 
to cost US$25,487 (27.9%) less than ROMI. Compared 
with W&R, EPAG cost US$34,436 (109.1%) more, while 
Table 3 Efficacy and costs
EPAG ROMI W&R ∆ EPAG–ROMI ∆ EPAG–W&R
All patients
severe bleeding (WhO 3–5) 2.2% 3.7% 6.5% –1.5% –4.2%
Costs (US$)
Drug costs 62,202 84,396 22,024 –22,194 40,178
administration costs 0 1,955 889 –1,955 –889
Routine care costs 486 486 486 0 0
Rescue medication costs 983 569 2,184 414 –1,201
Cost of severe bleeding (g3–5) 991 1,640 2,877 –650 –1,886
Cost of moderate bleeding (g2) 146 61 177 86 –31
adverse events costs 1,709 1,860 1,335 –151 373
Mortality costs 44 73 128 –29 –84
Total costs 66,560 91,039 30,099 –24,480 36,460
Splenectomized patients
severe bleeding (WhO 3–5) 1.0% 4.5% 9.5% –3.5% –8.5%
Costs (US$)
Drug costs 62,202 84,396 22,024 –22,194 40,178
administration costs 0 1,955 889 –1,955 –889
Routine care costs 486 486 486 0 0
Rescue medication costs 983 569 2,184 414 –1,201
Cost of severe bleeding (g3–5) 446 2,005 4,247 –1,559 –3,801
Cost of moderate bleeding (g2) 154 125 209 29 –55
adverse events costs 1,709 1,860 1,335 –151 373
Mortality costs 20 89 189 –69 –169
Total costs 65,998 91,485 31,562 –25,487 34,436
Non-splenectomized patients
severe bleeding (WhO 3–5) 3.5% 4.6% 4.9% –1.1% –1.3%
Costs (US$)
Drug costs 62,202 84,396 22,024 –22,194 40,178
administration costs 0 1,955 889 –1,955 –889
Routine care costs 486 486 486 0 0
Rescue medication costs 983 569 2,184 414 –1,201
Cost of severe bleeding (g3-5) 1,574 2,071 2,175 –498 –601
Cost of moderate bleeding (g2) 129 26 161 103 –32
adverse events costs 1,709 1,860 1,335 –151 373
Mortality costs 70 92 97 –22 –27
Total costs 67,151 91,455 29,350 –24,303 37,801
Note: all costs are reported in UsD.
Abbreviations: EPag, eltrombopag; ROMi, romiplostim; W&R, watch and rescue.
ROMI cost US$59,923 (189.9%) more. When assessing 
non-splenectomized patients, the cost difference between 
EPAG and ROMI was reduced, with EPAG estimated to 
cost US$24,303 (26.6%) less than ROMI. Compared with 
W&R, EPAG cost US$37,801 (128.8%) more, while ROMI 
cost US$62,104 (211.6%) more.
Drug costs comprised the vast majority 
of the price for all comparators.
In the analysis of severe bleeding, EPAG showed a 1.5% 
incremental benefit (1.66-fold improvement) over ROMI and 
a 4.2% benefit (2.90-fold improvement) over W&R in the ITT 
population, while ROMI showed an incremental benefit of 
2.8% (1.75-fold improvement) over W&R. In splenectomized 
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patients, these differences were exaggerated, with EPAG show-
ing a 3.5% incremental benefit (4.50-fold improvement) over 
ROMI and an 8.5% benefit (9.52-fold improvement) over W&R 
and ROMI showing an incremental benefit of 5.0% (2.12-fold 
improvement) over W&R. In non-splenectomized patients, the 
differences were tempered, as EPAG showed a 1.1% incremental 
benefit (1.32-fold improvement) over ROMI and a 1.3% benefit 
(1.38-fold improvement) over W&R. ROMI showed an incre-
mental benefit of 0.2% (1.05-fold improvement) over W&R 
when assessing severe bleeding in non-splenectomized patients.
Incremental cost-effectiveness ratios (ICERs; Table 4) were 
derived to further explore cost per severe bleeding event. When 
assessing cost per severe bleeding avoided in the ITT popula-
tion, EPAG dominated ROMI and had an ICER of US$862,071 
when compared to W&R, while ROMI had an ICER of 
US$2,197,935 compared to W&R. In splenectomized patients, 
EPAG again dominated ROMI and had a reduced ICER of 
US$403,994 when compared with W&R, while ROMI had a 
reduced ICER of US$1,192,142 compared with W&R. With 
regard to non-splenectomized patients, EPAG again dominated 
ROMI, with an increased ICER of US$2,802,913 when com-
pared with W&R, while ROMI had a more greatly increased 
ICER of US$26,696,956 compared with W&R.
sensitivity analyses
Uncertainty in the cost-effectiveness results for severe bleed-
ing events avoided was assessed with PSAs. Deterministic 
Table 4 iCERs for severe bleeding events avoided
Cost per severe bleeding event  
avoided (WHO 3–5)
ICER ICER
EPAG/ROMI EPAG/W&R ROMI/EPAG ROMI/W&R
iTT population Dominant 862,071 Dominated 2,197,935
splenectomized patients Dominant 403,994 Dominated 1,192,142
non-splenectomized patients Dominant 2,802,913 Dominated 26,696,956
Abbreviations: iCER, incremental cost-effectiveness ratio; EPag, eltrombopag; ROMi, romiplostim; W&R, watch and rescue; iTT, intent to treat.
Table 5 Psa parameters (iTT population)
Parameter Point estimate SE
Efficacy
Overall response – EPag 0.674 0.040
Overall response – ROMi 0.831 0.041
severe bleeding (WhO 3–5) – EPag 0.022 0.012
severe bleeding (WhO 3–5) – ROMi 0.071 0.028
Use of rescue medication – EPag 0.180 0.033
Use of rescue medication – ROMi 0.214 0.045
Costs
Drug costs, administration costs, routine care costs, cost of bleeding  
(severe and moderate), adverse events costs, mortality costs
Variable point estimate SE assumed at 20%
Abbreviations: Psa, probabilistic sensitivity analysis; iTT, intent to treat; sE, standard error; EPag, eltrombopag; ROMi, romiplostim.
sensitivity analyses were also intended to assess incremen-
tal cost-effectiveness for severe bleeding. However, these 
analyses were not feasible because EPAG was dominant over 
ROM I for severe bleeding and therefore the relevant base 
case ICER was unavailable.
For the PSA, probabilistic distributions were directly 
applied to the base case model for the ITT population. The 
parameters explored in the PSA are presented in Table 5. 
Point estimates and standard errors (SEs) were from the 
respective clinical trials.
PSA results were relatively consistent with the base case 
findings, where the majority of iterations were located in the 
southwest quadrant showing greater EPAG efficacy, with a 
lower EPAG cost (Figure 2).
Discussion
The previous cost-consequence model comparing EPAG to 
ROMI12 found that costs per responder for EPAG, ROMI, 
and W&R were US$64,314, US$58,990, and US$118,314, 
respectively. However, key limitations in this analysis were 
identified.
In the analysis by Li et al,12 epidemiology estimates for 
patient flow were not presented. Additionally, there was no 
formal comparison of trial, population, or settings to deter-
mine if proper comparators were used. Instead, naïve analyses 
were used to compare the trial data, and no assessment was 
made to ensure the trials were comparable. When a deviation 
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from the transitivity assumption exists, a model based on an 
ITC is more likely to validly compare clinical trial data.34
Further limiting the Li et al12 analysis, adverse event and 
mortality costs were not included, and the only endpoint 
included was cost per responder based on platelet count 
(which is a problematic endpoint when determining any sort 
of clinical or economic benefit, as response is not necessarily 
associated with tangible implications). Additionally, wastage 
analysis was not presented. Finally, no sensitivity analyses 
were performed to explore the uncertainty of their results. 
These gaps were all addressed in the present study.
In our model, following ITC adjustment, the rate of severe 
bleeding in EPAG was 2.2% compared to 3.7% with ROMI, 
which accounted for the difference in bleeding-related costs. 
In the ITT population, EPAG, ROMI, and W&R had total 
estimated costs of US$66,560, US$91,039, and US$30,099, 
respectively, with drug costs comprising most of the price 
for all comparators. The lower total cost of EPAG and higher 
severe bleeding events avoided led EPAG to dominate ROMI. 
When compared to W&R in our assessment, EPAG had a 
higher total cost and a resulting ICER of US$862,071 per 
severe bleeding event avoided. When assessing subgroups 
in our analysis, EPAG generally showed the most favorable 
results in the splenectomized population subgroup, dominat-
ing ROMI for severe bleeding event avoided. PSA results 
were relatively consistent with the base case findings.
Our study had several limitations. Because of incon-
sistent reporting in the literature, endpoint definitions in 
the trials varied occasionally, making direct matching and 
data  selection challenging. Rituximab and splenectomy, 
two common treatments for cITP, could not be included as 
comparators due to differences in patient characteristics and 
study design.16 The time horizon used in this model was rela-
tively short but allowed modeling of within-trial endpoints 
without the need for extrapolation techniques. Lastly, since 
there is currently no established cost-effectiveness threshold 
for severe bleeding events avoided, the interpretation of the 
ICER results presented can be challenging.
To our knowledge, this is the most comprehensive cost-
consequence model comparing EPAG with ROMI in adults 
with cITP who have had an insufficient response to cortico-
steroids, immunoglobulins, or splenectomy. This is an area 
of interest to physicians and health care decision-makers 
who are seeking to determine the best available treatment 
options for these patients. The results of our analysis indicate 
that EPAG is cost-effective for the treatment of cITP when 
assessing cost per severe bleeding event avoided. Additional 
analyses are planned to investigate cost comparisons between 
EPAG and ROMI in pediatric patients.
Conclusion
Overall, EPAG was dominant (less expensive with fewer 
severe bleeding events) compared with ROMI and had 
notably fewer severe bleeding events compared with W&R. 
Further evaluations that incorporate long-term extrapolation 
and preference-based outcomes (quality-adjusted life year 
and life year) would be meaningful additions to the evidence 
base for treatment of cITP.
Figure 2 Cost-effectiveness plane (EPag vs ROMi).
Abbreviations: EPag, eltrombopag; ROMi, romiplostim.
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